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Abstract
Background: Nuclear protein in testis (NUT) midline carcinomas (NMC) are rare, highly aggressive epithelial
neoplasms, characterised by protein expression of NUT-fusion proteins which reflects the genetic translocation
between chromosome 15 and 19. NMC occurs mainly in midline structures, but there are reports regarding
occurrence in structures outside the midline.
We investigated specimens from 519 surgically resected lung carcinomas and carcinoid tumours for the presence of
NUT protein using immunohistochemistry. Normal testis and two previously confirmed NMCs served as positive
controls.
Findings: All 483 evaluable cases (278 adenocarcinomas, 140 squamous cell carcinomas, 30 large cell carcinomas,
7 small cell carcinomas, 10 undifferentiated carcinomas and 18 carcinoids) were completely negative for expression
of NUT protein.
Conclusion: NUT gene rearrangement does not seem to be relevant in primary pulmonary carcinomas or carcinoid
tumours of the lung.
Nuclear protein in testis (NUT) midline carcinomas
(NMC) are rare, highly aggressive epithelial neoplasms
with a median survival of 6.7 months [1]. They were ori-
ginally described in midline structures above the dia-
phragm in paediatric and adolescent age groups, but their
occurrence in older age groups and in other anatomic
locations are described [2–4]. Since the first reports there
are now indications of higher prevalence of NMC in
adults than first anticipated [1].
NMCs are poorly differentiated neoplasms with mor-
phologic and immunophenotypic features of undifferen-
tiated carcinoma and squamous cell carcinoma [5]. They
are genetically defined by chromosomal rearrangements
of the NUT gene on chromosome 15; in approximately
70 % the gene is fused to bromodomain-containing pro-
tein 4 (BRD4) on chromosome 19 resulting in t(15;19)
translocation. The remaining cases harbour BRD3 or
other rare or uncharacterised fusion partners [2, 6].
Only a few cases of NMC with putative origin in the
lung have been reported [5, 7–11].
Due to the relatively new discovery of this entity and
the presumed rarity of this disease, underrecognition is
probable [12].
Patients with surgically treated lung carcinomas gener-
ally have prolonged survival compared to patients with
inoperable disease, but preoperative biopsy interpretation
and exact histopathological classification is frequently
challenging due to scarce amount of tissue. Immuno-
histochemical markers as thyroid transcribing factor-1
(TTF-1), Napsin A, p63 and p40 are often helpful in clas-
sification, but these markers do not predict the biological
or metastatic potential. Still, detailed histopathological
and genetic subclassification is increasingly demanded in
the quest for personalised therapy, but should be balanced
against tissue economics and prioritisation of relevant
analyses.
The occurrence of NUT positive cases among surgi-
cally treated lung cancers are to the best of our know-
ledge not known, but is putatively low, and large series
describing NMC in the lung are lacking [13]. It has been
suggested that all low-differentiated tumours devoid of
glandular differentiation and of non-skin origin should
be tested for the presence of NUT protein [12]. To ex-
plore the eventual occurrence of NUT expression, and
the relevance of NUT immunohistochemical analysis
in routine diagnostics, we examined a large cohort of
* Correspondence: mlundive@ous-hf.no
1Department of Pathology, Oslo University Hospital, Radiumhospitalet 0310,
Oslo, Norway
3Ullernchausseen 70, N-0310 Oslo, Norway
Full list of author information is available at the end of the article
© 2015 Lund-Iversen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lund-Iversen et al. Diagnostic Pathology  (2015) 10:156 
DOI 10.1186/s13000-015-0395-9
surgically treated lung cancers for NUT expression by a
monoclonal antibody in a tissue micro array (TMA) set.
Materials and methods
Tumour tissue was obtained from a cohort of lung can-
cer patients in stage Ia-IV surgically resected at the Oslo
University Hospital – Rikshospitalet during the period
2006 – 2013. Written informed consent was obtained
from all patients and the project was approved by the re-
gional ethics committee. Twenty-two tissue micro array
(TMA) blocks were prepared from 519 surgical speci-
mens from different intrathoracical locations. All major
histological types were included, and all grades of differ-
entiation were represented. One mm punch biopsies in
triplicate were selected from representative tumour areas
based on hematoxylin & eosin stained slides from the
tumours. In addition the TMA set contained normal
lung tissue, lymphoid tissue and metastatic tissue in
lymph nodes. The morphological classifications were
given in routine pathological reports based on the surgi-
cal specimen.
Immunohistochemistry
Freshly cut 4 μm sections were immunostained on a
Ventana Benchmark Ultra platform with a rabbit mono-
clonal antibody to NUT protein, the clone C52B1 from
Cell Signaling Technology, product number 3625, at
1:200 dilution. Ventana/Roche CC1 pretreatment buffer
(“standard”, ie 64 min) was used for antigen retrieval.
Detection system was OptiView DAB IHC Detection
Kit, product number 760–700, Ventana Medical Systems/
Roche Diagnostics, used with OptiView HQ Universal
Linker, thus constituting a highly sensitive 3 layer detec-
tion system. Control sections containing NUT positive
and negative tissue (normal testis and tonsil respectively)
were included on every TMA slide. As a supplementary
control, sections from two previously confirmed NMC
cases were prepared concomitantly. Staining of all slides
was performed in one single run on the Ventana platform.
Findings
A total of 483 tumours were assessable for the anti NUT
staining, the remaining samples were missing. 247 were
from males and 236 from females, with median age 66.3
[range 33.9 - 87.0] years. Patient and tumour characteris-
tics of the assessable cases are shown in Table 1. Approxi-
mately 20 % of the non-small cell carcinomas were poorly
differentiated, and 10 % well differentiated (not shown).
Every punch was evaluated by three consultant patholo-
gists (MLI, KKG, EB). The previously confirmed NUT
cases and the positive controls from testis had distinct
nuclear staining without any background (Fig. 1a,b). All
the tumour tissue, normal lung tissue and lymphoid tissue
were completely negative for NUT staining (exemplified
in Fig. 1c,d). Some alveolar macrophages had unspecific
cytoplasmic staining (Fig. 2). None of the samples had
equivocal staining.
Discussion
There is an increased demand for accurate diagnosis and
predictive tests in lung cancer.
Carcinomas harbouring NUT translocation are poten-
tially treatable with selective bromodomain extra terminal
(BET) inhibitors [14] which are available through ongoing
phase I clinical trials (e.g. GSK525762 (NTC01587703)
and TEN-010 (NCT01987362)). We have therefore inves-
tigated a large cohort of surgically resected lung cancers
for the presence of NUT protein with immunohistochem-
istry. In 483 evaluable specimens of lung tumours from
different intrathoracic locations we did not find any cases
with NUT expression.
The sensitivity and specificity for the C52 B1 antibody
is 87 and 100 % respectively among non-germ cell tu-
mours [15], and the variance might be explained by
different fusion partners to NUT. In our material none
of the tumours had staining scored as faint or difficult to
interpret. Approximately 20 % of the surgically resected
Table 1 Characteristics of assessable tumours
Characteristic (n = 483) Number Percentage











Squamous cell carcinoma 140 29.0
Large cell carcinoma 30 6.2
Small cell carcinoma 7 1.4
Carcinoid 18 3.7
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non-small cell carcinomas in this material were poorly
differentiated. These are the cases thought to be most
likely NUT-positive, but neither of these stained posi-
tively in our material.
The golden standard for defining NMC is fluorescence
in situ hybridization (FISH) with probes against NUT
and any eventual fusion partner. The NUT-fusion protein
product, investigated in this cohort, is highly predictive for
the genetic translocation in tumour tissue [15]. The ab-
sence of use of FISH technique in this cohort marginally
weakens the results, and we cannot exclude the possibility
that a minority of the cases are false negative.
Although we studied a cohort of mostly early stage
lung cancers, and we therefore cannot formally exclude
the possibility that the cohort does not reflect more ad-
vanced, inoperable lung cancers, still almost 15 % of the
cases were in stage III or IV. We therefore believe our
findings to be universal regardless of resectability.
In conclusion, NUT-expressing primary carcinoma of
the lung does not seem to be an underrecognised entity.
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Fig. 1 NUT-positive controls from testis (a) and one previously confirmed NUT midline carcinoma (b). NUT-negative lung carcinoma tissue (c, d)
Fig. 2 Unspecific cytoplasmic staining in alveolar macrophages
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